Cancer Cell Biology
Butyrate response factor 1 enhances cisplatin sensitivity in human head and neck squamous cell carcinoma cell lines
Article first published online: 4 MAY 2005
Copyright © 2005 Wiley-Liss, Inc.
International Journal of Cancer
Volume 117, Issue 1, pages 32–40, 20 October 2005
How to Cite
Lee, S. K., Kim, S. B., Kim, J. S., Moon, C. H., Han, M. S., Lee, B. J., Chung, D. K., Min, Y. J., Park, J. H., Choi, D. H., Cho, H. R., Park, S. K. and Park, J. W. (2005), Butyrate response factor 1 enhances cisplatin sensitivity in human head and neck squamous cell carcinoma cell lines. Int. J. Cancer, 117: 32–40. doi: 10.1002/ijc.21133
- Issue published online: 2 AUG 2005
- Article first published online: 4 MAY 2005
- Manuscript Accepted: 31 JAN 2005
- Manuscript Received: 22 NOV 2004
- Korean Research Foundation
Cisplatin is a widely used chemotherapeutic agent in head and neck squamous cell carcinoma (HNSCC). Resistance to cisplatin is a common feature of HNSCC. To identify genes that may regulate cisplatin sensitivity, we carried out a cDNA microarray analysis of gene expression in cisplatin-sensitive and cisplatin-resistant HNSCC-derived cell lines. Among genes differentially expressed by cisplatin treatment, we have confirmed the elevated expression of butyrate responsive factor 1 (BRF1) in cisplatin-sensitive HNSCC cells and have demonstrated that the expression level of BRF1 is associated with cisplatin-sensitivity. Specific inhibition of BRF1 expression using an antisense oligodeoxynucleotide (ODN) decreased the cisplatin-sensitivity and, on the contrary, overexpression of BRF1 increased cisplatin-sensitivity in HNSCC cells. Elevated expression of BRF1 decreased the level of the human inhibitor of apoptosis protein-2 (cIAP2) and increased the caspase-3 activity in HNSCC cells. In addition, elevated expression of BRF1 decreased the expression level of enhanced green fluorescent protein (EGFP) linked to a 3′ terminal AU-rich element (ARE) of cIAP2 mRNA. These findings demonstrate that BRF1 expression enhanced cisplatin sensitivity in HNSCC cells by reducing the levels of cIAP2 mRNA. © 2005 Wiley-Liss, Inc.